Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
1998-11-12
2003-11-25
Marschel, Ardin H. (Department: 1631)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S069100, C530S300000
Reexamination Certificate
active
06653446
ABSTRACT:
This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is human hypoxanthine-(guanine) phosphoribosyl transferase-2, sometimes hereinafter referred to as “HPRT-2”. The invention also relates to inhibiting the action of such polypeptides.
In higher animals, nucleases are secreted by the pancreas and enzymatically hydrolyze nucleic acids to yield, ultimately, the free purine and pyrimidine bases. If not salvaged and re-used, the free bases are degraded further and the end-products excreted. In some vertebrates, including the primates, the dalmatian dog, birds and some reptiles, the end-product of purine degradation is uric acid, whereas in other mammals and reptiles, and also in mollusks, the end-product is allantoin.
The degradation of purines to the end-product, uric acid in man has been intensively studied, since genetic aberrations of this pathway are known. The major purines, adenine and guanine, are first converted into xanthine, which is then oxidized by the complex flavoprotein xanthine oxidase to uric acid and a superoxide radical which undergoes conversion to hydrogen peroxide by the action of superoxide dismutase. In the presence of HPRT, however, a phosphoribosyl group is added to adenine and guanine from PRPP (phosphoribosyl pyrophosphate) to form AMP or GMP with the simultaneous loss of pyrophosphate (PP
i
), and these may be re-used.
Isotopic studies on vertebrates that excrete uric acid have shown it to derive from both exogenous and endogenous nucleic acids. Only about 0.5 grams of uric acid is excreted daily by the normal person, although up to 5 grams of free purines are formed daily. Evidently, the greater part of the free purines are salvaged or recycled. Uric acid is present in blood largely as monosodium urate, however, both the free acid and the urate salts are relatively insoluble in water, with the result that in some individuals uric acid precipitates and crystallizes in the urine, subsequently forming kidney stones and causing damage to this organ. Uric acid deposits are also formed in cartilaginous tissues, to produce gout, which apparently results from over-production of uric acid. This disease can be alleviated by treatment with the drug allopurinol. Allopurinol is an analog of hypoxanthine. Allopurinol inhibits xanthine oxidase and thus decreases the formation and accumulation of uric acid.
The salvage of purines in mammalian cells is facilitated by the conversion of hypoxanthine (adenine) and guanine to their respective mononucleotide forms, IMP and GMP by HPRT via an ordered, bi-bi reaction mechanism (Davidson, B. L., et al., J. Biol. Chem., 264:520-525 (1989)). A total defect in this gene is the cause of Lesch-Nyhan Syndrome in humans, which is marked by severe retardation, hyperuricemia, hyperuricaciduria, and severe neurological dysfunction (Kelley, W. N., et al., Science, 155:1682-1684 (1967)). Partial loss of this activity results in the over-production of uric acid which subsequently leads to precocious gout and uric acid nephrolithiasis.
Applicants have discovered an HPRT-2 gene which has been transfected into a heterologous expression system, producing a protein with properties consistent with its characterization as a member of the HPRT family.
Sequencing inaccuracies are a common problem when attempting to determine polynucleotide sequences. Accordingly, the sequence of
FIGS. 1A-1C
is based on several sequencing runs and the sequencing accuracy is considered to be at least 97%.
In accordance with one aspect of the present invention, there is provided a novel putative mature polypeptide which is HPRT-2, as well as fragments, analogs and derivatives thereof. The polypeptide of the present invention is of human origin.
In accordance with another aspect of the present invention, there are provided polynucleotides (DNA or RNA) which encode such polypeptides.
In accordance with yet a further aspect of the present invention, there is provided a process for producing such polypeptides by recombinant techniques.
In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such polypeptides, or polynucleotides encoding such polypeptides for therapeutic purposes, for example, to treat Lesch-Nyhan syndrome, precocious gout, uric acid nephrolithiasis, uricaciduria, renal failure (nephropathy), kidney stones and anemia.
In accordance with yet a further aspect of the present invention, there are provided antibodies against such polypeptides.
In accordance with yet another aspect of the present invention, there are provided antagonists to such polypeptides, which may be used to inhibit the action of such polypeptides, for example, in the treatment of African Sleeping sickness, obesity, advanced primary renal diseases, myocardial infarction, hypertension, hypo- and hyperparathyroidism, psoriasis, myxedema and proliferative hematopoietic disease.
These and other aspects of the present invention should be apparent to those skilled in the art from the teachings herein.
REFERENCES:
patent: 4749570 (1988-06-01), Poznansky
patent: 5082670 (1992-01-01), Gage et al.
patent: 5108921 (1992-04-01), Low et al.
patent: 5118601 (1992-06-01), Gruber
patent: RE34387 (1993-09-01), Holmes et al.
patent: 94/17183 (1994-08-01), None
patent: 97/42320 (1997-11-01), None
Biochemistryby A.L. Lehninger (Published by Worth Publishers, Inc., 70 Fifth Ave., NY, NY 10011, pp. 109-122, 1970.*
Olaru et al., Revue Roumaine De Biochimie, vol. 18, No. 2, pp. 131-137 (full document) (1981).*
Davidson et al., Purine and Pyrimidine Metabolism in Man VIII, Part B, [Published by Plenum Press, New York, New York] pp. 105-108, (1991).*
Davidson et al., Advances in Experimental Medicine and Biology, vol. 309B, pp. 105-108. (Citation and Abstract Only), 1991*
Olaru et al., Revue Roumaine De Biochimie, vol. 18, No. 2, pp. 131-137 (Citation Only), 1981.*
1990 Sigma Chemical Company Catalog [Publ. by Sigma Chemical Company, P.O. Box 14508, St. Louis, Missouri], p. 1100, 1990.*
Olsen et al., J. Biol. Chem., 249(13):4030-4037 (1974).
Melton et al., Proc. Natl. Acad. Sci. USA, 81:2147-2151 (1984).
Patel et al., Somatic Cell and Molecular Genetics, 10(5):483-493 (1984).
Sculley et al., Hum. Genet., 90:195-207 (1992).
Yip et al., Biochem., 19:1849-1856 (1980).
Yuan et al., Biochem., 31:806-810 (1992).
Wu et al., Nature Genetics, 3:235-240 (1993).
Genbank Entry Acc. No. T00169 (1992).
Genbank Entry Acc. No. T00115 (1992).
Genbank Entry Acc. No. T23947 (1994).
Genbank Entry Acc. No. T24112 (1994).
Genbank Entry Acc. No. T24119 (1994).
Genbank Entry Acc. No. T00696 (1992).
Genbank Entry Acc. No. T11051 (1993).
Genbank Entry Acc. No. T02687 (1993).
Genbank Entry Acc. No. T00217 (1992).
Genbank Entry Acc. No. T00154 (1992).
Genbank Entry Acc. No. Z47172 (1995).
Genbank Entry Acc. No. L25928 (1993).
Genbank Entry Acc. No. L25927 (1993).
Genbank Entry Acc. No. L26978 (1995).
Genbank Entry Acc. No. A20700 (1994).
Genbank Entry Acc. No. A20702 (1994).
Genbank Entry Acc. No. I06859 (1994).
Hassett et al., Biochem., 30(42):10141-10149 (1991).
Adkins et al., Am. J. Hum. Gen., 52:598-608 (1993).
Jolly et al., PNAS, USA, 80:477-481 (1983).
Johnson et al., Biological Abstracts, 69(7):4678 (1980).
Miller et al., PNAS, USA, 80:4709-4713 (1983).
Palella et al., Gene, 80:137-144 (1989).
Anderson, Science, 226:401-409 (1984).
Ghangas et al., PNAS, USA, 72(10):4147-4150 (1975)
Harper et al., Lange Medical Publ., Los Altos, 406-408 (1977).
Brown, The Washington Post (Dec. 8, 1995).
U.S. patent application Ser. No. 09/912,292, Rosen et al.
Adams Mark D.
Bednarik Daniel P.
Rosen Craig A.
Human Genome Sciences Inc.
Human Genome Sciences Inc.
Marschel Ardin H.
LandOfFree
Human hypoxanthine- (guanine) phosphoribosyl transferase-2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human hypoxanthine- (guanine) phosphoribosyl transferase-2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human hypoxanthine- (guanine) phosphoribosyl transferase-2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3147922